Absci Rockets on Positive ABS-201 Data and $100M Financing Backed by Eli Lilly

Eli Lilly participates in Absci’s $100M equity offering to fund ABS-201, a novel prolactin receptor antibody showing strong safety in Phase 1 for pattern hair loss and endometriosis.